Single Molecule Array (Simoa) Assay Services:
- Ultrasensitive fg/ml LLOQ for low abundance analyte quantitation
- Robust immunoassays for Neurobiological Markers such as Neurofilament Light Chain (NF-L), Amyloid peptides (Aβ), and Tau protein
- High precision digital ELISA provides accurate and reproducible data
- See below for representative data
Understanding the role of protein biomarkers in various disease states is essential, as are the most robust tools for examining your therapeutic candidates modulate these biomarkers. For your sample testing needs, PBL can help you measure your analyte(s) of interest that are in low abundance or in difficult matrices. Our scientists communicate with you building a transparent, collaborative environment and eliminating costly project missteps.
Contact Our Service Scientists
Key Features offered by Simoa Platform:
- Single well digital ELISA with femtogram per milliliter (fg/ml) sensitivity for quantitation of many low abundance analytes
- Compatible with various sample matrices such as CSF, serum, and plasma
- Provides a high degree of precision, accuracy, and reproducibility with < 10% inter-assay CV and intra-assay CV
Powered by Quanterix Single Molecule Array technology, Lexington, MA, U.S.A.
4 Citations
- Loppi, S.H. et al., (2023), "Increased fatty acid metabolism and decreased glycolysis are hallmarks of metabolic reprogramming within microglia in degenerating white matter during recovery from experimental stroke", J. Cerebral Blood Flow & Metabolism, 0(0):1, DOI: 10.1177/0271678X231147298 (link)
- Giannisis, A. et al., (2022), "Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease", Alzheimer's Research & Therapy, 14:115, DOI: 10.1186/s13195-022-01058-9 (link)
- Chiappelli, J. et al., (2018), "Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia", Neuropaschopharmacology, 43:1675, DOI: 10.1038/s41386-018-0038-4 (link)
- Zanin-Zhorov, A. et al., (2017), "Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10", J. Immunol. 198(10):3809, DOI: 10.4049/jimmunol.1602142 (link)